CHATSWORTH, Calif.--(BUSINESS WIRE)--CHAD Therapeutics, Inc. (AMEX:CTU) announced today that it has closed the sale of the assets related to its transfilling oxygen business for $1.825 million in cash, pursuant to an asset purchase agreement. As a result of the sale, CHAD will discontinue production and sales of its transfilling oxygen products.
